The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
The Pentagon will deploy U.S. forces to the Middle East on the heels of the attack on Saudi Arabian oil facilities, United States Secretary of Defense Mark Esper announced...Defenseread more
CNBC did a deep dive through the most recent Wall Street research to find stocks that analysts say are underappreciated.Marketsread more
Shares of MasterCard are up 46% this year, and 1120% since 2011, getting a boost from the strong U.S. consumer.Investingread more
Trade with China is the 'big unknown' for the Federal Reserve as it decides how best to support the U.S. economy, says Council on Foreign Relations Director of International...Futures Nowread more
Lobbying experts said the visit is likely an attempt to be in lawmakers' ears as they consider legislation that would impact Facebook.Technologyread more
Yardeni Research's Edward Yardeni believes the U.S. economy is picking up steam.Trading Nationread more
Iran's audacious drone and cruise missile attack on Saudi Arabia's oil producing facilities has provided a critical test yet for the Trump administration's foreign policy. A...Politicsread more
Chinese trade negotiators suddenly canceled a visit to meet U.S. farmers after they wrapped up trade talks in Washington this week.Marketsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
Bristol-Myers Squibb, whose high-profile Opdivo immunotherapy failed an important lung-cancer trial last summer, sharply raised its 2016 profit forecast after strong quarterly sales of other leading medicines.
The U.S. drugmaker on Thursday predicted 2016 earnings of $2.80 to $2.90 a share, up from its previous forecast range of $2.55 to $2.65.
Bristol-Myers, whose shares rose 5 percent in premarket trading, said it expects 2017 earnings of $2.85 to $3.05 per share.
Sales of Opdivo, which treats melanoma and lung cancer, tripled to $920 million in the third quarter, but trailed forecasts by $27 million.
Opdivo had been considered the leader among a new class of cancer drugs called PD-1 inhibitors until August, when researchers said it failed to slow progression of symptoms in previously untreated patients with advanced lung cancer.
Making matters worse for Opdivo, researchers earlier this month said Merck's rival Keytruda prolonged the life of similar patients, and on Monday, it became the first of new immunotherapy drugs approved in the United States for initial lung cancer treatment.
The company said it authorized a new $3 billion share repurchase program, in addition to the $1.1 billion remaining under an authorization in 2012. And it predicted flat operating expenses through 2020, which analysts said should help profit margins.
"We believe today's updates should begin to address Wall Street concerns on Bristol's near-term earnings outlook" in the wake of Opdivo's setbacks, JP Morgan analyst Chris Schott said in a research note.
Sales of Yervoy, an older melanoma treatment, jumped 19 percent to $285 million, $45 million above expectations, while sales of leukemia treatment Sprycel grew 15 percent to $472 million, $25 million above forecasts.
Eliquis, used to prevent blood clots and partnered with Pfizer, jumped 90 percent to $884 million, $71 million above expectations, helped by compelling clinical trial data.
It was not immediately clear how much of an impact price increases had on sales of Bristol-Myers drugs.
Bristol-Myers earned $1.2 billion, or 72 cents per share in the quarter, compared with $706 million, or 42 cents per share, a year ago. Revenue jumped 21 percent to $4.9 billion, about $200 million above forecasts.
Excluding special items, it earned 77 cents per share, well above expectations of 65 cents per share, according to Thomson Reuters I/B/E/S.
Despite Bristol-Myers' rally on Thursday, its shares have fallen 31 percent since the unfavorable Opdivo lung cancer data was reported on Aug. 5.